Literature DB >> 15581962

The use of transrectal ultrasound to biopsy pelvic masses in women.

Christopher Giede1, Ants Toi, William Chapman, Barry Rosen.   

Abstract

OBJECTIVES: The goal of this study was to review our experience with transrectal ultrasound (TRUS)-guided biopsies in women with a pelvic mass, with respect to obtaining an adequate sample, the influence of biopsy results on patient management, and patient tolerance. STUDY
METHODS: We conducted a chart review of all women at the Princess Margaret Hospital (PMH) that had been clinically referred for TRUS-guided biopsies of a pelvic mass. Data collected included patient age, previous type of malignancy, size and location of lesion being biopsied, postbiopsy diagnosis, and subsequent management. Statistics were purely descriptive.
RESULTS: Eight women have had this procedure at PMH. The smallest size of lesion biopsied was 1.7 x 1.4 x 2.3 cm. In all eight women, the tissue obtained was adequate for the determination of a histological diagnosis and subsequently influenced patient management. The procedure was well tolerated and there were no complications.
CONCLUSION: TRUS-guided biopsy of a pelvic mass is a feasible method of establishing a pathological diagnosis. In this small series of patients, it was found to be accurate, well tolerated, and useful in guiding patient management. In selected patients, the TRUS biopsy provides a useful alternative to transabdominal and transvaginal biopsy.

Entities:  

Mesh:

Year:  2004        PMID: 15581962     DOI: 10.1016/j.ygyno.2004.08.039

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  2 in total

Review 1.  Ultrasound-guided genitourinary interventions: principles and techniques.

Authors:  Byung Kwan Park
Journal:  Ultrasonography       Date:  2017-05-29

2.  Transvaginal Ultrasound-Guided Core Biopsy-Experiences in a Comprehensive Cancer Centre.

Authors:  Dániel Lengyel; Ildikó Vereczkey; Krisztina Kőhalmy; Kiarash Bahrehmand; Zoltán Novák
Journal:  Cancers (Basel)       Date:  2021-05-25       Impact factor: 6.639

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.